Standardization of HER2 testing: results of an international proficiency-testing ring study. (Q51918651)

17 April 2018

title

Standardization of HER2 testing: results of an international proficiency-testing ring study. (English)

1 reference

17 April 2018

8

Marc J van de Vijver

1 reference

17 April 2018

1

Mitch Dowsett

1 reference

17 April 2018

Wedad M Hanna

2

1 reference

17 April 2018

Mark Kockx

3

1 reference

17 April 2018

Frederique Penault-Llorca

4

1 reference

17 April 2018

Josef Rüschoff

5

1 reference

17 April 2018

Thorsten Gutjahr

6

1 reference

17 April 2018

Kai Habben

7

1 reference

17 April 2018

publication date

30 March 2007

1 reference

17 April 2018

published in

Modern Pathology

1 reference

17 April 2018

volume

20

1 reference

17 April 2018

issue

5

1 reference

17 April 2018

page(s)

584-591

1 reference

17 April 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.3800774

exact match

0 references

cites work

Cancer incidence and mortality in Europe, 2004

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

The biology of erbB-2/neu/HER-2 and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

HER2 as a prognostic factor in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

21 January 2018

Testing for HER2 status

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

HER-2 and choice of adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

Assessment of HER-2/neu Status in Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800774

7 January 2021

10.1038/MODPATHOL.3800774

Identifiers

DOI

1 reference

17 April 2018

PubMed ID

17396141

1 reference

17 April 2018